Kratom-derived compounds just moved a step closer to formal federal scheduling, and this time it’s in writing. On October 14th, the Drug Enforcement Administration published its revised Notice of Intent in the Federal Register, laying out updated concentration thresholds for 7-hydroxymitragynine (commonly called 7-OH) and mitragynine pseudoindoxyl. According to the Federal Register notice, these are proposed Schedule I controls, not a done deal yet.

What Does the DEA’s October 14 Federal Register Notice Actually Say?

The notice of intent addresses two kratom-derived compounds: 7-hydroxymitragynine and mitragynine pseudoindoxyl. Per the Federal Register notice, DEA intends to place both substances in Schedule I when either one, or their combined amount, exceeds a specified threshold.

That threshold, recommended by the Department of Health and Human Services in an October 8, 2026 letter, works two ways. A product crosses the line if it contains more than 1 milligram per gram (solid products) or 1 milligram per milliliter (liquid products) of 7-OH, mitragynine pseudoindoxyl, or both combined. It also crosses the line if the ratio of mitragynine to those compounds falls below 100 to 1. HHS designed this approach to separate products whose alkaloid makeup resembles botanical kratom from products that have been deliberately concentrated or enhanced.

This revised threshold replaces an earlier, lower one that HHS proposed in July 2025, which DEA used in a notice of intent published around July 7, 2026. That earlier notice is being formally withdrawn in this same Federal Register issue. Meanwhile, the notice also touches on MGM-15 and MGM-16, two related substances addressed in a separate but connected Federal Register action.

Is This a Final Rule, or Just a Proposal?

This is the procedural detail that’s easy to miss if you only read headlines. The document published October 14 is a notice of intent, not a completed temporary scheduling order. DEA cannot legally issue the actual order until at least 30 days after this notice and after notifying HHS, per the Federal Register notice.

So nothing has changed yet in terms of what’s legally controlled based on this specific document alone. What has changed is that the federal government moved from describing revised thresholds in summaries and agency statements to publishing the actual regulatory text. Manufacturers, testing labs, and compliance teams now have the authoritative language to review, including the exact unit thresholds and ratio calculations, instead of relying on paraphrased versions of a press release.

What Happens to the Existing Order on Mitragynine Pseudoindoxyl?

Here’s where things get a little layered. Back on August 26, 2026, DEA issued a temporary order placing mitragynine pseudoindoxyl, along with MGM-15 and MGM-16, into Schedule I without any threshold at all. According to the Department of Justice’s October 9, 2026 press release, those controls remain active during this new 30-day notice period.

In plain terms, the August 26 order on mitragynine pseudoindoxyl stays effective right now. It will remain in place until it either expires on its own or until DEA formally publishes the new threshold-based temporary order and withdraws the previous one, whichever happens first. There’s no gap in enforcement during this transition. Attorney General Todd Blanche summed up the department’s stance bluntly in the same release: “Dangerous and addictive opioids do not belong behind convenience store counters.”

What Is 7-OH, and What Does It Actually Do?

7-hydroxymitragynine is a minor alkaloid found naturally in the kratom plant (Mitragyna speciosa), typically in trace amounts. It’s also a metabolite your body produces when it processes mitragynine, the main active compound in kratom leaf. The problem the DEA and HHS have flagged isn’t kratom leaf itself. It’s the growing market of products, often sold in gas stations and smoke shops, where 7-OH has been chemically concentrated far beyond what occurs naturally.

The FDA addressed this directly in a July 2025 press release, describing 7-OH as “a concentrated byproduct of the kratom plant” rather than a representation of the plant in its natural state. FDA Commissioner Marty Makary put it plainly: “7-OH is an opioid that can be more potent than morphine.” That’s not marketing language. 7-OH binds to mu-opioid receptors, the same receptors targeted by morphine, oxycodone, and fentanyl.

Is 7-OH a Painkiller That Doesn’t Cause Overdose Risk?

This claim comes up a lot online, and it’s worth addressing directly because it’s not accurate. The idea that 7-OH relieves pain without the overdose or respiratory risks associated with traditional opioids isn’t supported by the available research.

According to the American College of Medical Toxicology’s position statement, 7-OH does appear to relieve pain in animal studies, and it’s actually more potent than mitragynine at producing that effect. But the same studies found that 7-OH produces opioid-like respiratory depression, meaning reduced breathing rate and volume, that was fully reversed by naloxone, the standard opioid overdose antidote. Repeated dosing in animal models also produced tolerance and withdrawal symptoms consistent with other opioids.

In other words, 7-OH behaves like an opioid because, pharmacologically, it is one. It has no FDA-approved medical use in humans, no established safe dosing, and there’s no scientific basis for the claim that it carries less overdose risk than other opioids. ACMT also notes that combining 7-OH with alcohol, benzodiazepines, or other opioids would be expected to increase the risk of respiratory depression and overdose, the same way those combinations do with any opioid.

Frequently Asked Questions

---

• Czechia’s “Lex Kratom” Bill Could Quietly Choke Its Cannabis Industry
• Department of Cannabis Control provides notice of modifications
• Germany’s 1% Hemp Bill Heads to Parliament as Farms Vanish
• Greece’s 0.3% THC Rule Just Became a False Comfort Blanket
• NIMH Provides Guidance to Psychadelic Researchers for Advanced Studies